Evaluation of the efficacy of sofosbuvir and velpatasvir in HCV-infected Japanese patients with decompensated cirrhosis: a prospective study in real life settings.
Not Applicable
Recruiting
- Conditions
- decompensated cirrhotic patients with hepatitis C virus
- Registration Number
- JPRN-UMIN000035711
- Lead Sponsor
- Toranomon Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Child-Pugh A
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sustained virological response (SVR) at 12 weeks after the end of treatment (EOT)
- Secondary Outcome Measures
Name Time Method SVR at 24 weeks after the EOT incidence rate of adverse events durig treatment the change of Child-Pugh score at 12 and 24 weeks after the EOT from baseline
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of sofosbuvir and velpatasvir contribute to HCV clearance in decompensated cirrhosis patients?
How does the efficacy of sofosbuvir/velpatasvir compare to interferon-based therapies in Japanese HCV cirrhotic populations?
Which biomarkers correlate with sustained virologic response to sofosbuvir and velpatasvir in HCV-infected decompensated cirrhosis patients?
What adverse events are reported with sofosbuvir/velpatasvir in HCV patients with Child-Pugh B/C decompensated cirrhosis?
How do sofosbuvir/velpatasvir regimens compare to other DAA combinations like glecaprevir/pibrentasvir in HCV cirrhotic populations?